News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 37–72
- Matches
- 266
- Sources here
- 23
- Companies here
- 9
Search results
Stored financial headlines
Active search
266 matching headlines
Ticker or company: RAREMain company stories
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
USA Rare Earth stock falls 9.4% after missing Q2 revenue and loss estimates
USA Rare Earth shares dropped 9.4% in after-hours trading after reporting Q2 2026 results that missed analyst expectations for revenue and adjusted net loss. The company posted an operating loss of $46.314 million and revenue of $5.821 million, falling short of estimates. Despite the …
USAR
main company
Sharemaestro market context
Price below Trend Line
52 weeks +25.9% · Next-week setup positive 61.7%
USA Rare Earth Stock Falls After Q2 Miss on Both Top and Bottom Lines
USA Rare Earth (NASDAQ:USAR) shares fell after the company reported a Q2 adjusted loss of 15 cents per share and revenue of $5.82 million, missing consensus estimates of 13 cents per share loss and $8.05 million revenue, respectively. Despite the financial miss, the company …
USAR
main company
Sharemaestro market context
Price below Trend Line
52 weeks +25.9% · Next-week setup positive 61.7%
Ultragenyx to license generic DOJOLVI to Esjay starting Jan 1, 2033 under settlement
Ultragenyx announced a settlement with Esjay, resolving patent litigation concerning DOJOLVI. Under the agreement, Ultragenyx will grant Esjay a non-exclusive, royalty-free license to market a generic version of DOJOLVI beginning January 1, 2033, with a potential extension to July 1, 2033, pending pediatric exclusivity. …
RARE
main company
Sharemaestro market context
Trend signal active
52 weeks -11.0%
USA Rare Earth Inc Q2 2026 Earnings Call Summary
USA Rare Earth Inc Q2 2026 Earnings Call Summary - Moby Strategic Architecture and Market Dynamics Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. …
USAR
main company
Sharemaestro market context
Price below Trend Line
44 weeks -39.9%
Ultragenyx Pharmaceutical Inc. (RARE) Investor Outlook: Nearly 100% Upside Potential According to Analyst Ratings
Ultragenyx Pharmaceutical Inc. (RARE), focused on rare genetic diseases, shows significant upside potential, with analysts setting an average target price of $52.84, nearly double its current $26.80. Despite current negative EPS and significant R&D investments, the company's robust product pipeline, strategic collaborations, and positive …
RARE
main company
Sharemaestro market context
Trend signal active
52 weeks -11.0%
USA Rare Earth Reports Second Quarter 2026 Financial Results
USA Rare Earth announced its Q2 2026 financial and operational results, highlighted by a cash balance of $1.53 billion and revenues of $5.8 million. The company made significant strategic progress, including finalizing definitive agreements with the U.S. Department of Commerce for up to $1.6 …
USAR
main company
Sharemaestro market context
Price below Trend Line
52 weeks +25.9% · Next-week setup positive 61.7%
USA Rare Earth Q2 Earnings Call Highlights
USA Rare Earth Inc Q2 2026 Earnings Call Summary - Moby Strategic Architecture and Market Dynamics Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. …
USAR
main company
Sharemaestro market context
Price below Trend Line
52 weeks +25.9% · Next-week setup positive 61.7%
Ultragenyx Pharmaceutical's (RARE) Buy Rating Reiterated at HC Wainwright
HC Wainwright has reiterated its "buy" rating for Ultragenyx Pharmaceutical (RARE) with a $50 price target, suggesting a 93% upside from its current stock price. This aligns with a "Moderate Buy" consensus among analysts, who project an average target of $57.82. The biopharmaceutical company …
RARE
main company
Sharemaestro market context
Trend signal active
52 weeks -11.0%
How Investors Are Reacting To Ultragenyx Pharmaceutical (RARE) Q2 Revenue Gain And Narrower Net Loss
Ultragenyx Pharmaceutical (RARE) reported a Q2 2026 revenue gain of US$214 million, up from US$167 million year-over-year, and a narrower net loss of US$92 million compared to US$115 million. While these results support the investment case for its rare disease and gene therapy portfolio, …
RARE
main company
Sharemaestro market context
Trend signal active
52 weeks -11.0%
Is Q2 Revenue Growth And Narrower Loss Altering The Investment Case For Ultragenyx Pharmaceutical (RARE)?
On August 4, 2026, Ultragenyx Pharmaceutical Inc. reported second-quarter revenue of US$214 million versus US$167 million a year earlier, while quarterly net loss narrowed to US$92 million from US$115 million and basic loss per share from continuing operations improved to US$0.90 from US$1.17. Despite …
RARE
main company
Sharemaestro market context
Trend signal active
52 weeks -11.0%
Has Ultragenyx Pharmaceutical (RARE) Fallen Far Enough To Avoid Overvaluation?
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Ultragenyx Pharmaceutical stock is coming off a difficult longer term stretch, with the share price down about 72.1% over five years. Current valuation checks …
RARE
main company
Sharemaestro market context
Trend signal active
52 weeks -11.0%